Should glucagon‐like peptide‐1 receptor agonist treatment be withheld in preoperative management?
Journal of Diabetes · 2023-09 · 15 (9) · 712-713
DOI: 10.1111/1753-0407.13469 ↗Kurz gefasst
Editorial in der Zeitschrift Journal of Diabetes, online erschienen am 19.09.2023. Verfasst von Zachary Bloomgarden. Beteiligte Einrichtung: Department of Medicine, Division of Endocrinology, Diabetes, and Bone Disease, Icahn School of Medicine at Mount Sinai, New York, NY, USA. Hauptthemen laut MEDLINE: Glucagon-Like Peptide-1 Receptor. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 11 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Medicine, Division of Endocrinology, Diabetes, and Bone Disease, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
ORCID-Profile: Zachary Bloomgarden
Zitieren
APA
Bloomgarden, Z. (2023). Should glucagon‐like peptide‐1 receptor agonist treatment be withheld in preoperative management?. Journal of Diabetes, 15(9), 712-713. https://doi.org/10.1111/1753-0407.13469
Vancouver
Bloomgarden Z. Should glucagon‐like peptide‐1 receptor agonist treatment be withheld in preoperative management?. Journal of Diabetes. 2023;15(9):712-713. doi:10.1111/1753-0407.13469
BibTeX
@article{Bloomgarden2023,
author = {Bloomgarden, Zachary},
title = {Should glucagon‐like peptide‐1 receptor agonist treatment be withheld in preoperative management?},
journal = {Journal of Diabetes},
year = {2023},
volume = {15},
number = {9},
pages = {712--713},
doi = {10.1111/1753-0407.13469}
}
EUVIMED